tert-butyl [1,1-dimethyl-3-(2-oxo-2,3-dihydrobenzimidazol-1-yl)propyl]carbamate | 910377-40-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: tert-butyl [1,1-dimethyl-3-(2-oxo-2,3-dihydrobenzimidazol-1-yl)propyl]carbamate
• 英文别名: tert-butyl [1,1-dimethyl-3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]carbamate；tert-butyl [1,1-Dimethyl-3-(2-oxo-2,3-dihydro-benzimidazol-1-yl)-propyl]-carbamate；tert-butyl N-[2-methyl-4-(2-oxo-3H-benzimidazol-1-yl)butan-2-yl]carbamate
• CAS: 910377-40-1
• 化学式: C₁₇H₂₅N₃O₃
• 分子量: 319.404
• InChiKey: PEDIUEMILOVQSS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  70.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl [1,1-dimethyl-3-(2-oxo-2,3-dihydrobenzimidazol-1-yl)propyl]carbamate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.5h， 以86%的产率得到3-(3-amino-3-methylbutyl)-5-methyl-1H-benzimidazol-2-one;hydrochloride
  参考文献：
  名称：

  Medicament Combinations for the Treatment of Respiratory Diseases

  摘要：

  本发明涉及新的药物组合物，除了一个或多个，最好是1号通用公式中的一个化合物外，其中A、B、R1、X、n和m的含义如权利要求和说明书中所给，至少还包含另一种活性物质2，以及它们的制备方法和作为药物组合物的用途。

  公开号：

  US20070203125A1
• 作为产物：
  描述：

  N,N'-羰基二(1,2,4-三氮唑) 、 tert-butyl N-[4-(2-amino-5-methylanilino)-2-methylbutan-2-yl]carbamate 以 四氢呋喃 为溶剂， 以59%的产率得到tert-butyl [1,1-dimethyl-3-(2-oxo-2,3-dihydrobenzimidazol-1-yl)propyl]carbamate
  参考文献：
  名称：

  Medicament Combinations for the Treatment of Respiratory Diseases

  摘要：

  本发明涉及新的药物组合物，除了一个或多个，最好是1号通用公式中的一个化合物外，其中A、B、R1、X、n和m的含义如权利要求和说明书中所给，至少还包含另一种活性物质2，以及它们的制备方法和作为药物组合物的用途。

  公开号：

  US20070203125A1

文献信息

• New betamimetics for the treatment of respiratory complaints
  申请人：Bouyssou Thierry

  公开号：US20060063817A1

  公开（公告）日：2006-03-23

  The present invention relates to compounds of formula 1 wherein the groups n, m, B, X and R 1 may have the meanings given in the claims and specification, processes for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

  本发明涉及公式1的化合物，其中n、m、B、X和R1的含义如权利要求和说明书中所给，以及它们的制备过程和作为药物组合物的用途，尤其是作为治疗呼吸系统疾病的药物组合物的用途。
• BENZIMIDAZOLONE DERIVATIVES
  申请人：Ando Kazuo

  公开号：US20090298811A1

  公开（公告）日：2009-12-03

  This invention relates to compounds and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula (I) or pharmaceutically acceptable salts thereof, wherein: A, B, R 1 , R 2 and R 3 are each as described herein. These compounds are useful in the treatment of a condition mediated by CB2 receptor binding activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, spasticity, epilepsy, Tourette's syndrome, Parkinson's disease, neuroprotection, anxiety, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, cachexia, nausea, emesis, chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma, dermatitis, seasonal allergic rhinitis, gastroesophageal reflux disease (GERD), constipation, diarrhea, functional gastrointestinal disorder, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, psoriasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glomerulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasodialation, hypertension, vasculitis, myocardial infarction, cerebral ischemia, reversible airway obstruction, adult respiratory disease syndrome, chronic obstructive pulmonary disease (COPD), cryptogenic fibrosing alveolitis and bronchitis.

  本发明涉及化合物和方法，用于治疗由CB1受体活性在哺乳动物主体中介导的疾病，包括人类，其包括向需要该治疗的哺乳动物施用化合物的治疗有效量的公式(I)或其药用可接受盐，其中：A、B、R1、R2和R3如本文所述。这些化合物在治疗由CB2受体结合活性介导的疾病中有用，如但不限于炎症性疼痛、伤害性疼痛、神经性疼痛、纤维肌痛、慢性腰痛、内脏疼痛、急性脑缺血、疼痛、慢性疼痛、急性疼痛、带状疱疹后神经痛、神经病、神经痛、糖尿病性神经病、艾滋病相关神经病、神经损伤、类风湿性关节炎疼痛、骨关节炎疼痛、背部疼痛、癌症疼痛、牙痛、纤维肌痛、神经炎、坐骨神经痛、炎症、神经退行性疾病、痉挛、癫痫、托瑞特综合征、帕金森病、神经保护、焦虑、咳嗽、支气管痉挛、肠易激综合征（IBS）、炎症性肠病（IBD）、结肠炎、脑血管缺血、虚弱、恶心、呕吐、化疗诱导呕吐、类风湿关节炎、哮喘、克罗恩病、溃疡性结肠炎、皮炎、季节性过敏性鼻炎、胃食管反流病（GERD）、便秘、腹泻、功能性胃肠障碍、皮肤T细胞淋巴瘤、多发性硬化症、骨关节炎、牛皮癣、系统性红斑狼疮、糖尿病、青光眼、骨质疏松症、肾小球肾炎、肾缺血、肾炎、肝炎、脑中风、血管扩张、高血压、血管炎、心肌梗死、脑缺血、可逆气道阻塞、成人呼吸系统疾病综合征、慢性阻塞性肺疾病（COPD）、隐源性纤维化肺泡炎和支气管炎。
• Betamimetics for the treatment of respiratory complaints
  申请人：Boehringer Ingelheim International GmbH

  公开号：US07429583B2

  公开（公告）日：2008-09-30

  The present invention relates to compounds of formula 1 wherein the groups n, m, B, X and R1 may have the meanings given in the claims and specification, processes for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

  本发明涉及式1的化合物，其中n、m、B、X和R1基团可以具有在权利要求和说明书中给出的含义，制备它们的过程以及它们作为制药组合物的用途，尤其是作为治疗呼吸道疾病的制药组合物。
• Benzimidazolone derivatives as CB2 receptor ligands
  申请人：Pfizer Inc.

  公开号：US08138177B2

  公开（公告）日：2012-03-20

  This invention relates to compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein: A, B, R1, R2 and R3 are each as described herein, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by CB2 receptor binding activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma, dermatitis, seasonal allergic rhinitis, gastroesophageal reflux disease (GERD), constipation, diarrhea, functional gastrointestinal disorder, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, psoriasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glomerulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasculitis, myocardial infarction, cerebral ischemia, reversible airway obstruction, adult respiratory disease syndrome, chronic obstructive pulmonary disease (COPD), cryptogenic fibrosing alveolitis or bronchitis.

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其中：A、B、R1、R2和R3如下所述，并且包含这种化合物的组合物以及将这种化合物用于治疗由CB2受体结合活性介导的病症，例如但不限于炎性疼痛、伤害性疼痛、神经病性疼痛、纤维肌痛、慢性腰痛、内脏疼痛、急性脑缺血、疼痛、慢性疼痛、急性疼痛、带状疱疹后神经痛、神经病、神经痛、糖尿病神经病、艾滋病相关神经病、神经损伤、类风湿性关节炎疼痛、骨关节炎疼痛、背痛、癌痛、牙痛、纤维肌炎、神经炎、坐骨神经痛、炎症、神经退行性疾病、咳嗽、支气管收缩、肠易激综合征（IBS）、炎性肠病（IBD）、结肠炎、脑血管缺血、呕吐，如癌症化疗引起的呕吐，类风湿性关节炎、哮喘、克罗恩病、溃疡性结肠炎、哮喘、皮炎、季节性过敏性鼻炎、胃食管反流病（GERD）、便秘、腹泻、功能性胃肠障碍、皮肤T细胞淋巴瘤、多发性硬化症、骨关节炎、牛皮癣、系统性红斑狼疮、糖尿病、青光眼、骨质疏松症、肾小球肾炎、肾缺血、肾炎、肝炎、脑卒中、血管炎、心肌梗塞、脑缺血、可逆气道阻塞、成人呼吸系统疾病综合征、慢性阻塞性肺疾病（COPD）、隐源性纤维化性肺炎或支气管炎。
• MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES
  申请人：KONETZKI Ingo

  公开号：US20100297028A1

  公开（公告）日：2010-11-25

  The present invention relates to new medicament combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein A, B, R 1 , X, n and m may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

  本发明涉及新的药物组合物，除了含有一个或多个通式1中A、B、R1、X、n和m可能具有声明和说明书中给出的含义的化合物之外，还包含至少一种其他活性物质2，以及制备它们的方法和它们作为制药组合物的用途。